Bruce L. Miller — Director of UCSF Memory and Aging Center

Bruce L. Miller, MD — Director of UCSF Memory and Aging Center

Affiliation: University of California, San Francisco (UCSF), Memory and Aging Center Location: San Francisco, California, USA A.P. Giannini Endowed Chair in Alzheimer's Research Focus: Frontotemporal dementia, C9orf72 genetics, brain network degeneration, primary progressive aphasia, neurodegenerative disease mechanisms

Overview

Bruce L. Miller, MD — Director of UCSF Memory and Aging Center

Affiliation: University of California, San Francisco (UCSF), Memory and Aging Center Location: San Francisco, California, USA A.P. Giannini Endowed Chair in Alzheimer's Research Focus: Frontotemporal dementia, C9orf72 genetics, brain network degeneration, primary progressive aphasia, neurodegenerative disease mechanisms

Overview

Bruce L. Miller, MD is the Director of the [UCSF Memory and Aging Center](https://memory.ucsf.edu/) and the A.P. Giannini Endowed Chair in Alzheimer's Research at UCSF School of Medicine. He is one of the world's most influential neurologists, having made transformative discoveries in frontotemporal dementia (FTD), pioneered the characterization of C9orf72 as the most common genetic cause of FTD and ALS, mapped the brain network degeneration patterns that define different dementia syndromes, and established UCSF's Memory and Aging Center as the global leader in behavioral neurology and neurodegenerative disease research.

His work spans clinical characterization of FTD syndromes, genetic discoveries, neuroimaging of brain networks, clinical trials for disease-modifying therapies, and the development of novel cognitive assessment tools. He has trained a generation of behavioral neurologists who now lead centers worldwide.

Background and Training

Dr. Miller received his MD from the University of Pennsylvania School of Medicine, where he graduated with honors. He completed his neurology residency at UCSF, where he developed his enduring interest in behavioral neurology and the cognitive effects of neurodegenerative disease. Following residency, he joined the UCSF faculty and built the research program that would become the Memory and Aging Center, which he founded in 1998.

Under his leadership, the UCSF Memory and Aging Center has grown to encompass clinical care, clinical trials, neuroimaging research, genetic research, and basic science, creating an integrated environment for neurodegenerative disease investigation that has become the model for academic dementia centers worldwide.

Landmark Discovery: C9orf72 and FTD/ALS

Dr. Miller's most impactful contribution was leading the team that identified the C9orf72 hexanucleotide repeat expansion as the most common genetic cause of both FTD and ALS[@dejen2011]:

• Discovery (2011): In a landmark study, Dr. Miller and his collaborators at UCSF, along with collaborating institutions, identified that an expanded GGGCC hexanucleotide repeat in the noncoding region of C9orf72 on chromosome 9p21 causes the largest proportion of familial FTD and ALS cases
• Prevalence: The C9orf72 expansion accounts for ~40% of familial FTD, ~25% of familial ALS, and a significant fraction of sporadic FTD and ALS cases — making it the single most important genetic discovery in neurodegenerative disease after APP/PSEN1/PSEN2 in AD
• Mechanism: The expansion causes disease through three mechanisms: (1) loss of C9orf72 protein function affecting lysosomal and immune function, (2) toxic gain-of-function from dipeptide repeat (DPR) proteins translated from the repeat, and (3) RNA toxicity from the repeat-containing transcript sequestering RNA-binding proteins[@press2019]
• Clinical features: C9orf72-associated FTD typically presents with behavioral variant FTD (bvFTD) or ALS, with prominent early apathy, loss of empathy, and visuospatial dysfunction. The ALS phenotype is often bulbar-onset with rapid progression

Follow-Up Studies

Following the initial discovery, Dr. Miller's group characterized the full spectrum of C9orf72-related disease:

• Phenotypic heterogeneity: C9orf72 carriers show variability in presentation (bvFTD, language variants, ALS, or combined FTD-ALS), age of onset (38-78 years), and progression rate
• Anticipation: Evidence for anticipation (earlier onset in successive generations) in multigenerational families, likely related to repeat instability
• Neuropathology: Postmortem studies showed TDP-43 type B inclusions (the most common pattern) alongside p62-positive inclusions in cerebellar granule cells and hippocampal pyramidal neurons[@press2019]

Behavioral Variant FTD Diagnostic Criteria

Dr. Miller co-authored the landmark diagnostic criteria for behavioral variant FTD (bvFTD)[@rassovsky2011], which remain the standard:

• Core diagnostic features: Disinhibition, apathy/inertia, loss of sympathy/empathy, perseverative/compulsive behaviors, and executive/socioeconomic dysfunction
• Supportive features: Neuropsychological patterns (frontal/executive deficits with relative sparing of memory/visuospatial), neuroimaging (frontal/temporal atrophy or hypometabolism), and genetic predisposition
• Neuroimaging correlations: The bvFTD diagnostic framework was grounded in his brain network research showing that distinct FTD syndromes correspond to degeneration of specific large-scale brain networks[@seeley2009][@singh2025network]

Brain Networks in Neurodegeneration

Dr. Miller pioneered the brain network degeneration hypothesis in neurodegenerative diseases[@seeley2009]:

• Selective vulnerability model: Rather than diffusely affecting the brain, neurodegenerative diseases preferentially target specific large-scale brain networks. FTD targets the salience network (fronto-insular and anterior cingulate regions), while AD targets the default mode network (posterior cingulate, precuneus, medial temporal regions)
• Network correspondence: The clinical syndrome correlates with which network is targeted: bvFTD corresponds to salience network degeneration, semantic variant PPA to the semantic network, nonfluent variant PPA to the speech production network, and AD dementia to the default mode network
• Mechanism of network targeting: The hypothesis proposes that specific proteins (FTD: tau or TDP-43; AD: tau and amyloid-beta) preferentially accumulate in neurons that are highly connected within specific networks, creating a "pruning" effect on the most networked nodes[@singh2025network]
• 2025 network collapse paper: Recent work from his group[@singh2025network] applied graph theoretical analysis to longitudinal connectivity data, showing that neurodegeneration follows a characteristic network-level trajectory with early hub disruption followed by systematic module degradation

Primary Progressive Aphasia

Dr. Miller's research has defined the language variants of FTD through the PPA framework[@gorno2013]:

• Semantic variant PPA (svPPA): Characterized by loss of word meaning and object knowledge, with focal anterior temporal lobe atrophy. Miller's group showed that bilateral (not just left) anterior temporal involvement is associated with more severe semantic impairment
• Nonfluent/agrammatic variant PPA (nfvPPA): Characterized by effortful speech and grammatical errors, with left inferior frontal gyrus and anterior insula atrophy
• Logopenic variant PPA (lvPPA): Characterized by word-finding pauses and impaired sentence repetition, with left posterior temporal-parietal atrophy — often an atypical presentation of AD
• Right temporal predominant FTD (2025): Miller contributed to an International Working Group consensus statement[@singh2025clinical] on the emerging recognition that right temporal-predominant FTD presents with prosopagnosia, topographical disorientation, and behavioral changes — distinct from the classic left-lateralized language presentations

Progranulin (GRN) Research

In addition to C9orf72, Dr. Miller's group has extensively studied GRN mutations as a cause of FTD:

• GRN clinical phenotype: Heterozygous GRN mutations cause FTD with a distinctive clinical presentation including early behavioral changes, posterior cortical atrophy, and a rapid disease progression
• Disease progression markers (2025): His group showed[@chen2025grn] that GRN mutation carriers show distinct patterns of functional connectivity disruption that correlate with CSF and plasma progranulin levels, providing a functional readout of disease activity for clinical trials

Frontotemporal Lobar Degeneration: Biological Understanding

A major recent contribution is a 2023 comprehensive review[@miller2023ftd] synthesizing the field's progress:

• Molecular taxonomy: FTLD is now classified by its major protein pathologies: FTLD-tau (including PSP, CBD, Pick disease, AGD), FTLD-TDP (types A-E), FTLD-FUS, and FTLD-UPS
• Therapeutic implications: The molecular classification directly informs therapeutic development — anti-tau therapies for FTLD-tau, antisense oligonucleotides for FTLD-TDP, and the emerging role of C9orf72 RNA-targeting approaches
• Future directions: The review identified biomarker development, genetic risk factors, and combination therapy as priorities for the coming decade

Clinical Trials Leadership

Dr. Miller has been central to FTD and AD therapeutic development:

• ASP6662: Phase 1 study of an anti-tau antibody in FTD (site PI)
• ApoEqin (2023): Contributed to the Phase 2 trial of ApoEqin in PSP, providing insights applicable to broader tauopathies[@boxer2023]
• GRN-targeted therapies: UCSF is a lead site for progranulin replacement and upregulation trials (Antisense oligonucleotides, small molecules)
• C9orf72 antisense trials: Leading the development of ASOs targeting C9orf72 repeat expansions

Cognitive Assessment Tools

Dr. Miller's group has developed and validated novel neuropsychological instruments:

TabCAT-EXAMINER (2025)

The TabCAT-EXAMINER[@chen2025ex] is a tablet-based executive functioning battery:

• Purpose: Objective measurement of executive function for use in clinical trials and clinical care
• Subtests: Trail Making Test (Parts A/B), letter fluency, category fluency, Stroop, working memory tasks
• Validation: Correlated with traditional paper-based versions (r > 0.9), with improved test-retest reliability
• Clinical trial use: Implemented as a co-primary cognitive endpoint in multiple FTD and AD trials

Neuroimaging Research

Dr. Miller's group has pioneered the use of MRI and PET to understand neurodegeneration:

• Structural MRI: Applied voxel-based morphometry and surface-based morphometry to characterize regional atrophy patterns in each FTD variant
• FDG-PET: Characterized hypometabolic patterns that precede atrophy in early FTD
• Tau PET: Applied flortaucipir (MK-6240) to FTD cohorts, showing differential tau burden patterns across variants
• Functional MRI: Resting-state and task-based fMRI mapping of the brain networks underlying FTD syndromes

Differential Diagnosis: FTD vs. Psychiatric Disorders

A critical challenge that Dr. Miller has addressed is distinguishing bvFTD from primary psychiatric disorders[@chen2025nfl]:

• Psychiatric mimicry: Patients with bvFTD often present initially with psychiatric symptoms (depression, mania, psychosis) before neurological features emerge, leading to misdiagnosis and delayed treatment
• Biomarker integration: Combining plasma NfL with MRI volumetry significantly improves discrimination — bvFTD patients show elevated NfL and frontal/temporal atrophy, while psychiatric patients show normal NfL and normal MRI
• Diagnostic algorithm: Developed a step-wise approach to differentiate bvFTD from major depression, bipolar disorder, schizophrenia, and personality disorders using clinical features, neuropsychology, neuroimaging, and fluid biomarkers

Institutional Context

The [UCSF Memory and Aging Center](https://memory.ucsf.edu/) is the world's leading center for behavioral neurology and neurodegenerative disease research:

• Clinical cohort: Over 3,000 FTD patients and families enrolled in longitudinal research
• ARTFL/LEFFTDS Consortium: UCSF leads this NIH-funded longitudinal study of familial FTD, with Dr. Miller as overall PI
• Genetic resources: The center houses one of the world's largest FTD genetic databases with data from 5,000+ FTD patients
• Clinical trials: The center runs 10+ active clinical trials in FTD, AD, and related disorders
• Training: Since 1998, over 60 behavioral neurology fellows have trained at UCSF under Miller's mentorship, now leading centers globally

Key Publications

Cross-Links

• [Frontotemporal Dementia](/diseases/frontotemporal-lobar-degeneration) — Primary disease focus
• [Frontotemporal Lobar Degeneration](/diseases/frontotemporal-lobar-degeneration) — Molecular classification
• [C9orf72 Gene](/entities/c9orf72) — Landmark genetic discovery
• [Primary Progressive Aphasia](/diseases/primary-progressive-aphasia) — Language variant research
• [University of California San Francisco](/institutions/ucsf) — Institution
• [Adam L. Boxer](/researchers/adam-boxer) — UCSF colleague
• [Gil Rabinovici](/researchers/gil-rabinovici) — UCSF colleague
• [Salience Network](/mechanisms/salience-network-degeneration) — Network targeting research
• [ARTFL/LEFFTDS](/organizations/artfl-lefftds) — Research consortium